HSL-IN-1 manufacturers
- HSL-IN-1
-
- $199.00
-
2026-09-10
- CAS:2095156-13-9
- Purity: 100.00%
- Supply Ability: 10g
- HSL-IN-1
-
- $199.00
-
2026-07-14
- CAS:2095156-13-9
- Purity: 100.00%
- Supply Ability: 10g
- HSL-IN-1
-
- $232.00
-
2025-08-22
- CAS:2095156-13-9
- Purity: 100.00%
- Supply Ability: 10g
|
| | HSL-IN-1 Basic information |
| Product Name: | HSL-IN-1 | | Synonyms: | HSL-IN-1;HSL IN 1,HSLIN1;Boronic acid, B-[5-chloro-2-[[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]carbonyl]amino]phenyl]- | | CAS: | 2095156-13-9 | | MF: | C19H13BClF3N2O4 | | MW: | 436.58 | | EINECS: | | | Product Categories: | | | Mol File: | 2095156-13-9.mol |  |
| | HSL-IN-1 Chemical Properties |
| density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 12.5 mg/mL (28.63 mM) | | pka | 7.40±0.53(Predicted) | | form | Solid | | color | White to off-white |
| | HSL-IN-1 Usage And Synthesis |
| Uses | HSL-IN-1 (compound 24b) is a potent and orally active hormone sensitive lipase (HSL) inhibitor (IC50=2 nM) with a significantly reduced reactive metabolite liability[1]. | | in vivo | HSL-IN-1 (3 mg/kg, p.o., single dose) exhibits potent antilipolytic effects and good oral bioavailability in male Wistar rats[1]. | Animal Model: | Male Wistar rats (7-8 weeks old, 200-250 g)[1] | | Dosage: | 3 mg/kg | | Administration: | Oral gavage (p.o.), single dose | | Result: | Significantly reduced plasma glycerol levels.
Cmax was 3.35 μg/mL, and AUC was 19.65 μg·h/mL. |
| | References | [1] Ogiyama T, et al. Identification of a novel hormone sensitive lipase inhibitor with a reduced potential of reactive metabolites formation. Bioorg Med Chem. 2017 Apr 1;25(7):2234-2243. DOI:10.1016/j.bmc.2017.02.045 |
| | HSL-IN-1 Preparation Products And Raw materials |
|